IL6 and COVID-19: Overall observed deactivation of various interleukin pathways in COVID-19 patients might be partially due to anti-IL-6 treatment (one patient) and/or potential glucocorticoid treatment (at least two COVID-19 patients received prednisolone while at the ICU).